JP2010534061A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534061A5
JP2010534061A5 JP2010517023A JP2010517023A JP2010534061A5 JP 2010534061 A5 JP2010534061 A5 JP 2010534061A5 JP 2010517023 A JP2010517023 A JP 2010517023A JP 2010517023 A JP2010517023 A JP 2010517023A JP 2010534061 A5 JP2010534061 A5 JP 2010534061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
protein
protease
fusion protein
activation domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010517023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/008786 external-priority patent/WO2009014650A2/en
Publication of JP2010534061A publication Critical patent/JP2010534061A/ja
Publication of JP2010534061A5 publication Critical patent/JP2010534061A5/ja
Withdrawn legal-status Critical Current

Links

JP2010517023A 2007-07-20 2008-07-18 組換えコレラ菌外毒素 Withdrawn JP2010534061A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96130807P 2007-07-20 2007-07-20
PCT/US2008/008786 WO2009014650A2 (en) 2007-07-20 2008-07-18 Recombinant vibrio cholerae exotoxins

Publications (2)

Publication Number Publication Date
JP2010534061A JP2010534061A (ja) 2010-11-04
JP2010534061A5 true JP2010534061A5 (https=) 2011-09-01

Family

ID=40282021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517023A Withdrawn JP2010534061A (ja) 2007-07-20 2008-07-18 組換えコレラ菌外毒素

Country Status (4)

Country Link
US (1) US8524241B2 (https=)
EP (1) EP2178559B1 (https=)
JP (1) JP2010534061A (https=)
WO (1) WO2009014650A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372537T3 (es) * 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
US8993295B2 (en) * 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009149281A1 (en) * 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
WO2011133704A2 (en) * 2010-04-20 2011-10-27 Whitehead Institute For Biomedical Researh Modified polypeptides and proteins and uses thereof
RU2593715C2 (ru) * 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2730289A1 (en) * 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
WO2016146833A1 (en) * 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016207324A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Biomarkers for nad(+)−diphthamide adp ribosyltransferase sensitivity and resistance
CN106478773B (zh) * 2015-08-25 2021-09-14 三生国健药业（上海）股份有限公司 一种人工合成的新型信号肽
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN121513216A (zh) 2018-03-08 2026-02-13 应用分子转运公司 用于经口递送的毒素衍生的递送构建体
EP4083058A3 (en) * 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
AU2020327671A1 (en) * 2019-08-13 2022-03-03 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4380973A2 (en) 2021-08-02 2024-06-12 Yeda Research and Development Co. Ltd. Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0531434T3 (da) * 1990-05-11 2000-01-31 Us Health Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
WO1993025690A1 (en) * 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1687016A4 (en) * 2003-11-25 2009-07-29 Anjin Corp GENETIC VARIANT OF DIPHTHERIC TOXIN
US7550426B2 (en) * 2005-05-18 2009-06-23 Ghc Research Development Corporation Acetylated therapeutic procytotoxins
US8993295B2 (en) * 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
WO2009149281A1 (en) * 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof

Similar Documents

Publication Publication Date Title
JP2010534061A5 (https=)
Cooper et al. Soluble CD23 controls IgE synthesis and homeostasis in human B cells
Strijbis et al. Protein ligation in living cells using sortase
Suresh et al. The importance of ubiquitination and deubiquitination in cellular reprogramming
Skidgel et al. Cellular carboxypeptidases
Cruz‐Garcia et al. Stylar glycoproteins bind to S‐RNase in vitro
Sato et al. Further studies on the site-specific protein modification by microbial transglutaminase
HRP20191305T1 (hr) Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
JP2022109971A (ja) 細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
Fath et al. Association of yeast RNA polymerase I with a nucleolar substructure active in rRNA synthesis and processing
JP2017018125A5 (https=)
WO2023155901A1 (en) Mutant cytidine deaminases with improved editing precision
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
Kim et al. Improvement of recombinant hGM-CSF production by suppression of cysteine proteinase gene expression using RNA interference in a transgenic rice culture
BRPI1012321A8 (pt) Anticorpos anti-vegf e seus usos
Basu et al. A novel S100A8/A9 induced fingerprint of mesenchymal stem cells associated with enhanced wound healing
Herhaus et al. The emerging roles of deubiquitylating enzymes (DUBs) in the TGFβ and BMP pathways
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
Lipinszki et al. Ubiquitylation of Drosophila p54/Rpn10/S5a regulates its interaction with the UBA–UBL polyubiquitin receptors
Riffer et al. Mutational analysis of K28 preprotoxin processing in the yeast Saccharomyces cerevisiae
NZ589806A (en) Variant hedgehog-interacting protein (hhip1) and methods and uses thereof
US7485321B2 (en) Peyer's patch and/or M-cell targeting ligands
Islam et al. In vivo removal of N-terminal fusion domains from recombinant target proteins produced in nicotiana benthamiana
Karki et al. Intracellular trafficking and glycosylation of hydroxyproline-O-glycosylation module in tobacco BY-2 cells is dependent on medium composition and transcriptome analysis